Copyright © 2003 by the European Society of Cardiology.
Regular Articles
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes
The Global Registry of Acute Coronary Events (GRACE)
a The University and The Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK
b Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St. Michaels Hospital, University of Toronto, Toronto, Ontario, Canada
c University of Massachusetts Medical School, Worcester, MA, USA
d Duke University Medical Center, Durham, NC, USA
e University of Michigan Health System, Ann Arbor, MI, USA
f Royal Brompton & Harefield NHS Trust, London, UK
g Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland
* Corresponding author: Professor Keith A. A. Fox, Department of Cardiology, University of Edinburgh, Edinburgh EH3 9YW, UK. Tel.: +44-131-536-2742; fax: +44-131-536-2744
E-mail address: k.a.a.fox{at}ed.ac.uk
Received 19 December 2002; revised 22 April 2003; accepted 27 April 2003
Aims The extent to which hospital and geographic characteristics influence the time course of uptake of evidence from key clinical trials and practice guidelines is unknown. The gap between evidence and practice is well recognized but the factors influencing this disjunction, and the extent to which such factors are modifiable, remain uncertain.
Methods and results Using chronological data from the GRACE registry (n=12 666, July 1999 to December 2001), we test the hypothesis that hospital and geographic characteristics influence the time course of uptake of evidence-based guideline recommendations for acute coronary syndromes (ACS) with and without ST elevation. Certain therapies were widely adopted in both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients (aspirin >94% of all patients; beta-blockers 8595%) and changed only modestly over time. Significant increases in the use of low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors occurred in STEMI and NSTEMI patients in advance of published practice guidelines (September/November 2000) with marked geographical differences. The highest use of LMWH was in Europe in NSTEMI (86.8%) and the lowest in the USA (24.0%). Contrasting geographical variations were seen in the use of percutaneous coronary intervention (PCI) in NSTEMI: 39.5% USA, 34.6% Europe, 33.5% Argentina/Brazil, 25.0% Australia/New Zealand/Canada (JulyDecember 2001). Theuse of PCI was more than five times greater in hospitals with an on-site catheterization laboratory compared to centres without these facilities, and geographic differences remained after correction for available facilities.
Conclusions Hospital and geographical factors appear to have a marked influence on the uptake of evidence-based therapies in ACS management. The presentation and publication of major international guidelines was not associated with a measurable change in the temporal pattern of practice. In contrast, antithrombotic and interventional therapies changed markedly over time and were profoundly influenced by hospital and geographic characteristics.
Key Words: Acute coronary syndromes Low-molecular-weight heparin Glycoprotein IIb/IIIa inhibitors Percutaneous coronaryintervention Catheterization laboratory Temporal trends Guidelines
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. Bogaty, L. Boyer, S. Simard, F. Dauwe, R. Dupuis, B. Verret, T. Huynh, F. Bertrand, G. R. Dagenais, and J. M. Brophy Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2339 - 2346. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Lee, M. Tan, A. T. Yan, R. T. Yan, D. Fitchett, E. A. Grima, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndromes (ACS) Re Use of Cardiac Catheterization for Non-ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk: Reasons Why Physicians Choose Not to Refer Their Patients Arch Intern Med, February 11, 2008; 168(3): 291 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
O H Dabbous, F A Anderson Jr, J M Gore, K A Eagle, K A A Fox, R H Mehta, R J Goldberg, G Agnelli, P G Steg, and for the GRACE Investigators Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes Heart, February 1, 2008; 94(2): 159 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Faxon Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Current State of ST-Elevation Myocardial Infarction Care Circulation, July 10, 2007; 116(2): e29 - e32. [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF] |
||||
![]() |
K. A. A. Fox, P. G. Steg, K. A. Eagle, S. G. Goodman, F. A. Anderson Jr, C. B. Granger, M. D. Flather, A. Budaj, A. Quill, J. M. Gore, et al. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 JAMA, May 2, 2007; 297(17): 1892 - 1900. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Manfrini and R. Bugiardini Barriers to clinical risk scores adoption Eur. Heart J., May 1, 2007; 28(9): 1045 - 1046. [Full Text] [PDF] |
||||
![]() |
F. Fernandez-Aviles, J. J. Alonso, G. Pena, J. Blanco, J. Alonso-Briales, J. Lopez-Mesa, F. Fernandez-Vazquez, J. Moreu, R. A. Hernandez, A. Castro-Beiras, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial Eur. Heart J., April 2, 2007; 28(8): 949 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Hochman, G. A. Lamas, C. E. Buller, V. Dzavik, H. R. Reynolds, S. J. Abramsky, S. Forman, W. Ruzyllo, A. P. Maggioni, H. White, et al. Coronary Intervention for Persistent Occlusion after Myocardial Infarction N. Engl. J. Med., December 7, 2006; 355(23): 2395 - 2407. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ndrepepa, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, M. Seyfarth, J. Pache, J. Dirschinger, et al. Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions Circulation, November 7, 2006; 114(19): 2040 - 2046. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Moscucci and D Share Impact of health care initiatives on outcomes of acute coronary syndromes. Heart, March 1, 2006; 92(3): 293 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Fonarow In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes: Maximizing the Early and Long-term Benefits Chest, November 1, 2005; 128(5): 3641 - 3651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Thune, D. E. Hoefsten, M. G. Lindholm, L. S. Mortensen, H. R. Andersen, T. T. Nielsen, L. Kober, H. Kelbaek, and for the Danish Multicenter Randomized Study on Fib Simple Risk Stratification at Admission to Identify Patients With Reduced Mortality From Primary Angioplasty Circulation, September 27, 2005; 112(13): 2017 - 2021. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Bassand, S. Priori, and M. Tendera Evidence-based vs. 'impressionist' medicine: how best to implement guidelines Eur. Heart J., June 2, 2005; 26(12): 1155 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Schiele, N. Meneveau, M. F. Seronde, F. Caulfield, R. Fouche, G. Lassabe, D. Baborier, P. Legalery, J.-P. Bassand, and on behalf of the Reseau de Cardiologie de Franche Compliance with guidelines and 1-year mortality in patients with acute myocardial infarction: a prospective study Eur. Heart J., May 1, 2005; 26(9): 873 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF] |
||||
![]() |
J. S Kalus and L. R Moser Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction Ann. Pharmacother., March 1, 2005; 39(3): 481 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
O C Raffel and H D White Practising what is preached: the MINAP study Heart, September 1, 2004; 90(9): 969 - 971. [Full Text] [PDF] |
||||
![]() |
J S Birkhead, L Walker, M Pearson, C Weston, A D Cunningham, and A F Rickards Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP) Heart, September 1, 2004; 90(9): 1004 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Scott, C. P. Denaro, A. C. Hickey, C. Bennett, A. M. Mudge, D. C. Sanders, J. Thiele, and J. L. Flores Optimising care of acute coronary syndromes in three Australian hospitals Int. J. Qual. Health Care, August 1, 2004; 16(4): 275 - 284. [Abstract] [Full Text] [PDF] |
||||









